Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267


Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, Bega D, LeDoux MS, Shprecher DR, Anderson KE.

J Neurol Neurosurg Psychiatry. 2019 Jul 10. pii: jnnp-2018-319918. doi: 10.1136/jnnp-2018-319918. [Epub ahead of print]


Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.

Hauser RA, Kremens DE, Elmer LW, Kreitzman DL, Walsh RR, Johnson R, Howard R, Nguyen JT, Patni R.

J Parkinsons Dis. 2019;9(3):591-600. doi: 10.3233/JPD-181565.


Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease.

Hauser RA, Isaacson SH, Ellenbogen A, Safirstein BE, Truong DD, Komjathy SF, Kegler-Ebo DM, Zhao P, Oh C.

Parkinsonism Relat Disord. 2019 Mar 30. pii: S1353-8020(19)30192-0. doi: 10.1016/j.parkreldis.2019.03.026. [Epub ahead of print]


46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study.

Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE.

CNS Spectr. 2019 Feb;24(1):201. doi: 10.1017/S1092852919000397.


45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study.

Hauser RA, Fernandez HH, Stamler D, Davis MD, Factor SA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE.

CNS Spectr. 2019 Feb;24(1):200-201. doi: 10.1017/S1092852919000385.


35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia.

Anderson KE, Stamler D, Davis MD, Gross N, Hauser RA, Jarskog LF, Jimenez-Shahed J, Kumar R, Ochudlo S, McEvoy J, Fernandez HH.

CNS Spectr. 2019 Feb;24(1):193-194. doi: 10.1017/S1092852919000294.


34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities.

Anderson KE, Stamler D, Davis MD, Hauser RA, Jarskog LF, Jimenez-Shahed J, Kumar R, Ochudlo S, McEvoy J, Fernandez HH.

CNS Spectr. 2019 Feb;24(1):193. doi: 10.1017/S1092852919000282.


Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.

LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C; SPAN-PD Study Investigators.

Lancet Neurol. 2019 Feb;18(2):145-154. doi: 10.1016/S1474-4422(18)30405-8. Erratum in: Lancet Neurol. 2019 Mar;18(3):e2.


Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease.

Hauser RA, Biaggioni I, Hewitt LA, Vernino S.

Mov Disord Clin Pract. 2018 Nov 8;5(6):627-634. doi: 10.1002/mdc3.12695. eCollection 2018 Nov-Dec.


Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Charvin D, Medori R, Hauser RA, Rascol O.

Nat Rev Drug Discov. 2018 Nov;17(11):844. doi: 10.1038/nrd.2018.184. Epub 2018 Oct 12.


Help cure Parkinson's disease: please don't waste the Golden Year.

Hauser RA.

NPJ Parkinsons Dis. 2018 Sep 25;4:29. doi: 10.1038/s41531-018-0065-1. eCollection 2018. No abstract available.


Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Charvin D, Medori R, Hauser RA, Rascol O.

Nat Rev Drug Discov. 2018 Nov;17(11):804-822. doi: 10.1038/nrd.2018.136. Epub 2018 Sep 28. Review. Erratum in: Nat Rev Drug Discov. 2018 Oct 12;:.


Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials.

Chen JJ, Han Y, Tang J, Portillo I, Hauser RA, Dashtipour K.

Ann Pharmacother. 2018 Dec;52(12):1182-1194. doi: 10.1177/1060028018786954. Epub 2018 Jul 4.


Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.

Hauser RA, Pahwa R, Wargin WA, Souza-Prien CJ, McClure N, Johnson R, Nguyen JT, Patni R, Went GT.

Clin Pharmacokinet. 2019 Jan;58(1):77-88. doi: 10.1007/s40262-018-0663-4.


Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease.

Hauser RA, Ellenbogen A, Khanna S, Gupta S, Modi NB.

Neuropsychiatr Dis Treat. 2018 Mar 22;14:839-845. doi: 10.2147/NDT.S153321. eCollection 2018.


Tardive dyskinesia: Out of the shadows.

Hauser RA, Truong D.

J Neurol Sci. 2018 Jun 15;389:1-3. doi: 10.1016/j.jns.2018.02.009. Epub 2018 Feb 5. Review.


The nosology of tardive syndromes.

Frei K, Truong DD, Fahn S, Jankovic J, Hauser RA.

J Neurol Sci. 2018 Jun 15;389:10-16. doi: 10.1016/j.jns.2018.02.008. Epub 2018 Feb 6.


A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.

Lew MF, Brashear A, Dashtipour K, Isaacson S, Hauser RA, Maisonobe P, Snyder D, Ondo W.

Int J Neurosci. 2018 Jul;128(7):619-626. doi: 10.1080/00207454.2017.1406935. Epub 2018 Jan 17.


ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia.

Pahwa R, Hauser RA.

JAMA Neurol. 2017 Dec 1;74(12):1507-1508. doi: 10.1001/jamaneurol.2017.3205. No abstract available.


Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ.

Mov Disord. 2017 Dec;32(12):1701-1709. doi: 10.1002/mds.27131. Epub 2017 Aug 21.


ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.

Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ.

J Parkinsons Dis. 2017;7(3):511-522. doi: 10.3233/JPD-171134.


Valbenazine for the treatment of tardive dyskinesia.

Seeberger LC, Hauser RA.

Expert Opin Pharmacother. 2017 Aug;18(12):1279-1287. doi: 10.1080/14656566.2017.1353078. Epub 2017 Aug 2.


Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH.

Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.


Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.

Goetz CG, Stebbins GT, Chung KA, Nicholas AP, Hauser RA, Merkitch D, Stacy MA.

Mov Disord. 2017 Sep;32(9):1335-1336. doi: 10.1002/mds.27092. Epub 2017 Jun 24. No abstract available.


ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ.

JAMA Neurol. 2017 Aug 1;74(8):941-949. doi: 10.1001/jamaneurol.2017.0943.


A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, Simuni T; Parkinson Study Group STEADY‐PD III Investigators.

Ann Clin Transl Neurol. 2017 May 9;4(6):360-368. doi: 10.1002/acn3.412. eCollection 2017 Jun.


Design of a cluster-randomized minority recruitment trial: RECRUIT.

Tilley BC, Mainous AG 3rd, Smith DW, McKee MD, Amorrortu RP, Alvidrez J, Diaz V, Ford ME, Fernandez ME, Hauser RA, Singer C, Landa V, Trevino A, DeSantis SM, Zhang Y, Daniels E, Tabor D, Vernon SW.

Clin Trials. 2017 Jun;14(3):286-298. doi: 10.1177/1740774517690146. Epub 2017 Mar 19.


Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group.

Neurology. 2017 Jun 6;88(23):2198-2206. doi: 10.1212/WNL.0000000000004003. Epub 2017 May 10.


Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort.

Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA; NINDS NET-PD Investigators.

J Neurol Sci. 2017 Jun 15;377:137-143. doi: 10.1016/j.jns.2017.04.011. Epub 2017 Apr 11.


Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.

Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE.

Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26.


A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease.

Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, Klepiskaya OS, Kreitzman DL, Lew MF, Russell DS, Kadosh S, Litman P, Friedman H, Linvah N, The P B Study Group F.

Mov Disord. 2017 May;32(5):783-789. doi: 10.1002/mds.26941. Epub 2017 Apr 3.


KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.

Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.

Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21.


Caffeine, creatine, GRIN2A and Parkinson's disease progression.

Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T.

J Neurol Sci. 2017 Apr 15;375:355-359. doi: 10.1016/j.jns.2017.02.032. Epub 2017 Feb 17.


Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension.

White WB, Hauser RA, Rowse GJ, Ziemann A, Hewitt LA.

Am J Cardiol. 2017 Apr 1;119(7):1111-1115. doi: 10.1016/j.amjcard.2016.11.066. Epub 2017 Jan 6. Review.


Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.

Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S.

J Neurol Sci. 2017 Feb 15;373:116-123. doi: 10.1016/j.jns.2016.11.047. Epub 2016 Nov 23.


Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R.

JAMA Neurol. 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467.


Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease.

Valdés EG, O'Connor ML, Uc EY, Hauser RA, Andel R, Edwards JD.

Int J Neurosci. 2017 Oct;127(10):841-848. doi: 10.1080/00207454.2016.1269088. Epub 2016 Dec 20.


Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1.

Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC; NINDS NET-PD Investigators.

J Parkinsons Dis. 2017;7(1):117-127. doi: 10.3233/JPD-160965.


Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.

Wills AA, Elm JJ, Ye R, Chou KL, Parashos SA, Hauser RA, Bodis-Wollner I, Hinson VK, Christine CW, Schneider JS; NINDS NET-PD Investigators.

Parkinsonism Relat Disord. 2016 Dec;33:127-133. doi: 10.1016/j.parkreldis.2016.10.005. Epub 2016 Oct 8.


Communicating with participants during the conduct of multi-center clinical trials.

Augustine EF, Dorsey ER, Hauser RA, Elm JJ, Tilley BC, Kieburtz KK.

Clin Trials. 2016 Dec;13(6):592-596. Epub 2016 Aug 29.


Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.

François C, Rowse GJ, Hewitt LA, Vo P, Hauser RA.

BMC Neurol. 2016 Aug 18;16(1):143. doi: 10.1186/s12883-016-0665-5.


Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.

Espay AJ, LeWitt PA, Hauser RA, Merola A, Masellis M, Lang AE.

Lancet Neurol. 2016 Aug;15(9):954-966. doi: 10.1016/S1474-4422(16)30079-5. Review.


Long-term effects of rasagiline and the natural history of treated Parkinson's disease.

Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW; AFU Investigators.

Mov Disord. 2016 Oct;31(10):1489-1496. doi: 10.1002/mds.26724.


Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.

Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A.

Mov Disord. 2016 Sep;31(9):1366-72. doi: 10.1002/mds.26697. Epub 2016 Jul 19.


A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain.

Hauser RA, Lackner JB, Steilen-Matias D, Harris DK.

Clin Med Insights Arthritis Musculoskelet Disord. 2016 Jul 7;9:139-59. doi: 10.4137/CMAMD.S39160. eCollection 2016. Review.


Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.

Hauser RA, Heritier S, Rowse GJ, Hewitt LA, Isaacson SH.

Clin Neuropharmacol. 2016 Sep-Oct;39(5):220-6. doi: 10.1097/WNF.0000000000000168.


Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.

Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L.

BMC Neurol. 2016 Jun 7;16:90. doi: 10.1186/s12883-016-0610-7.


A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.

LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD.

Mov Disord. 2016 Sep;31(9):1356-65. doi: 10.1002/mds.26611. Epub 2016 Apr 19.


Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.

Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A; MODERATO Investigators.

Mov Disord. 2016 May;31(5):709-14. doi: 10.1002/mds.26617. Epub 2016 Mar 31.


Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.

Hauser RA, Abler V, Eyal E, Eliaz RE.

Int J Neurosci. 2016 Oct;126(10):942-6. doi: 10.3109/00207454.2016.1154552. Epub 2016 Mar 18.


Supplemental Content

Loading ...
Support Center